The U.S. Food and Drug Administration (FDA) has approved a generic version of leucovorin to treat a very rare neurological disorder related to folate deficiency in the brain. However, regulators and medical experts emphasize that the medication should not be considered a treatment for autism.
The decision follows months of confusion and public discussion about whether the drug might help people with autism spectrum disorder. After reviewing available scientific evidence, the FDA determined that leucovorin is appropriate only for a rare genetic condition that prevents enough folate, a form of vitamin B, from reaching the brain.
This development has drawn attention from doctors, researchers, and families affected by autism. Experts say the approval highlights the importance of relying on strong clinical evidence when considering treatments for complex neurological conditions.
Leucovorin is a laboratory created form of folate, also known as vitamin B9. The drug has been used for decades in medicine, particularly to reduce side effects from certain chemotherapy drugs and to treat some blood disorders.
The FDA’s new approval focuses on a rare genetic condition that disrupts the body’s ability to transport folate into the brain. When folate levels in the brain are too low, patients may develop neurological symptoms such as seizures, movement difficulties, and developmental problems.
According to the FDA, this condition affects fewer than one in one million people in the United States. Because the disorder is extremely rare, treatment options have been limited.
By approving leucovorin for this specific condition, the agency hopes to provide a targeted therapy that can help restore folate levels in the brain and potentially reduce neurological symptoms.
Interest in leucovorin expanded in 2025 after public comments suggested the drug might help children with autism.
At the time, U.S. officials said the medication was being evaluated as a potential treatment for autism related symptoms. Some early reports suggested that a portion of children with autism might benefit from improved folate activity in the brain.
These remarks sparked significant attention among parents, advocacy groups, and clinicians searching for new ways to support children with autism spectrum disorder.
However, the FDA later clarified that the evidence supporting leucovorin for autism treatment was not strong enough to justify approval for that purpose.
After further evaluation, regulators concluded that the most reliable scientific data supported only the treatment of the rare genetic folate disorder.
Complicating the issue was the retraction of a study earlier in 2026 that had suggested benefits of leucovorin for autism. Retractions occur when researchers or journals determine that a study’s findings cannot be relied upon due to methodological problems or other concerns.
Without consistent and well designed clinical trials, experts say it is difficult to determine whether the medication provides meaningful benefits for people with autism.
Autism researchers also point out that autism spectrum disorder is complex and involves many different biological pathways. As a result, treatments that work for one specific condition may not apply broadly to autism.
Several medical organizations recommend caution when considering leucovorin for autism related symptoms.
The American Academy of Pediatrics does not recommend using leucovorin as a treatment for children with autism. This includes cases where children have a condition known as cerebral folate deficiency.
Dr. Alycia Halladay of the Autism Science Foundation explained that the current evidence does not show that leucovorin benefits most individuals with autism.
She also warned that the drug’s safety in this context has not been clearly established. Some reports have linked leucovorin to side effects such as irritability, aggression, and hyperactivity in certain patients.
Because of these concerns, experts advise families to consult healthcare professionals before considering any off label use of the medication.
Despite the lack of clear scientific support, prescriptions for leucovorin increased significantly after public statements about its possible role in autism treatment.
A study published in The Lancet reported a 71 percent rise in prescriptions for children aged 5 to 17 during the three months following the announcement in September 2025.
Researchers say this spike illustrates how quickly medical practices can change when new potential treatments gain media attention.
David Mandell, an autism researcher at the University of Pennsylvania, noted that families have experienced confusion due to conflicting information.
Many parents searching for effective therapies may feel hopeful when a new possibility emerges, but later scientific clarification can create uncertainty about what treatments are actually supported by evidence.
The increase in demand has also created supply issues. Some families have reported difficulty filling prescriptions due to shortages.
To address this issue, the FDA said it will allow foreign manufacturers to help supply the drug. Expanding production sources may help stabilize availability and ensure patients with approved medical conditions can access the medication.
The drug’s original manufacturer, GSK, has stated that it does not plan to relaunch its version of leucovorin.
Health authorities say maintaining supply is especially important for patients with the rare genetic disorder targeted by the new approval.
Autism spectrum disorder affects millions of people worldwide and is characterized by differences in communication, behavior, and social interaction.
Scientists believe autism develops from a combination of genetic and environmental factors. However, there is still no single known cause or universal treatment.
Research continues to explore biological pathways that may contribute to autism. Some studies focus on metabolism, immune responses, or nutrient transport in the brain, including folate related pathways.
While these areas of research are promising, experts stress that potential treatments must be carefully tested through rigorous clinical trials before they can be widely recommended.
For families affected by autism, the FDA’s decision clarifies that leucovorin is approved only for a specific rare brain disorder involving folate transport problems.
Parents who are considering treatments related to folate metabolism should consult qualified healthcare professionals and review the latest research before making decisions.
Medical experts emphasize that evidence based care remains the safest approach when managing developmental and neurological conditions.
New research may eventually reveal additional therapies that improve outcomes for people with autism. Until then, clinicians recommend focusing on established treatments, supportive therapies, and individualized care plans.
This article is for informational and educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Medical research and recommendations may change over time. Individuals should consult qualified healthcare professionals for personalized medical guidance regarding medications, treatments, or health conditions. Statistical and clinical information presented in this article reflects general research trends and may not apply to every individual situation.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.